凝血因子IX Padua变体及高比活性变体的进化启示
该研究对凝血因子IX第338位进行全部20种氨基酸替换扫描,测定人源和犬源变体的比活性,发现hFIX-R338L活性最高,cFIX-R338L比野生型犬FIX高七倍,且野生型hFIX和cFIX活性最低。在血友病B犬基因治疗后证实cFIX-R338I比活性升高,筛查232例儿童血栓栓塞疾病未发现F9 R338变体。
要点
- hFIX-R338L是所测变体中比活性最高的,cFIX-R338L比野生型犬FIX高7倍。
- 野生型人FIX和犬FIX是所测变体中比活性最低的之一。
- 基因治疗后cFIX-R338I在血友病B犬体内比活性高于野生型FIX。
核心结论
- 进化压力倾向于限制而非最大化FIX活性,野生型FIX活性处于低水平。
研究设计与样本
- 对FIX第338位进行全部20种氨基酸替换扫描,测定人源和犬源变体比活性。
- 在血友病B犬基因治疗后评估cFIX-R338I的体内比活性。
- 筛查232例儿童血栓栓塞疾病患者的F9 R338变体。
主要发现
- hFIX-R338L是所测变体中比活性最高的。
- cFIX-R338L比活性为野生型cFIX的7倍。
- 野生型hFIX和cFIX是所测变体中比活性最低的之一。
- cFIX-R338I在血友病B犬基因治疗后体内比活性高于FIX-WT。
- 232例儿童血栓栓塞疾病中未发现F9 R338变体。
临床怎么用
- R338L等高比活性FIX变体是血友病B基因治疗的有前景候选。
- 评估FIX变体时需关注其血栓倾向,因R338L与罕见X连锁血栓形成风险相关。
局限性
- 儿童血栓栓塞疾病筛查样本量有限,未检出R338变体不能排除其人群频率极低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The high-specific-activity factor IX (FIX) variant Padua (R338L) is the most promising transgene for hemophilia B (HB) gene therapy. Although R338 is strongly conserved in mammalian evolution, amino acid substitutions at this position are underrepresented in HB databases. We therefore undertook a complete 20 amino acid scan and determined the specific activity of human (h) and canine (c) FIX variants with every amino acid substituted at position 338. Notably, we observe that hFIX-R338L is the most active variant and cFIX-R338L is sevenfold higher than wild-type (WT) cFIX. This is consistent with the previous identification of hFIX-R338L as a cause of a rare X-linked thrombophilia risk factor. Moreover, WT hFIX and cFIX are some of the least active variants. We confirmed the increased specific activity relative to FIX-WT in vivo of a new variant, cFIX-R338I, after gene therapy in an HB dog. Last, we screened 232 pediatric subjects with thromboembolic disease without identifying F9 R338 variants. Together these observations suggest a surprising evolutionary pressure to limit FIX activity with WT FIX rather than maximize FIX activity.
引用
- Samelson-Jones BJ, Finn JD, Raffini LJ, et al. Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variants. Blood Adv. 2021. PMID: 33656538. doi:10.1182/bloodadvances.2019000405
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。